Your browser is no longer supported. Please, upgrade your browser.
AMAG AMAG Pharmaceuticals, Inc. daily Stock Chart
AMAG Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-10.88 Insider Own3.10% Shs Outstand34.10M Perf Week-9.76%
Market Cap255.04M Forward P/E37.62 EPS next Y0.19 Insider Trans18.24% Shs Float33.48M Perf Month-10.54%
Income-368.90M PEG- EPS next Q-0.19 Inst Own- Short Float37.31% Perf Quarter-7.28%
Sales320.60M P/S0.80 EPS this Y-178.40% Inst Trans-4.24% Short Ratio22.39 Perf Half Y-41.00%
Book/sh7.73 P/B0.94 EPS next Y159.40% ROA-41.70% Target Price8.14 Perf Year-24.06%
Cash/sh3.55 P/C2.04 EPS next 5Y- ROE-96.40% 52W Range4.41 - 13.53 Perf YTD-40.35%
Dividend- P/FCF- EPS past 5Y-35.40% ROI-79.10% 52W High-46.34% Beta0.96
Dividend %- Quick Ratio1.40 Sales past 5Y21.40% Gross Margin64.70% 52W Low64.63% ATR0.55
Employees440 Current Ratio1.50 Sales Q/Q-9.40% Oper. Margin- RSI (14)43.98 Volatility6.62% 7.45%
OptionableYes Debt/Eq0.00 EPS Q/Q79.70% Profit Margin- Rel Volume0.51 Prev Close7.05
ShortableYes LT Debt/Eq1.07 EarningsMay 11 BMO Payout- Avg Volume557.79K Price7.26
Recom2.90 SMA20-3.42% SMA50-7.14% SMA200-20.97% Volume286,920 Change2.91%
Oct-30-19Downgrade Piper Jaffray Neutral → Underweight $9 → $6
Aug-01-19Initiated H.C. Wainwright Buy $16
Jun-11-19Initiated Barclays Overweight $19
Mar-20-19Initiated SunTrust Hold
Dec-14-18Reiterated B. Riley FBR Buy $29 → $20.50
Nov-06-18Downgrade JP Morgan Neutral → Underweight
Jun-15-18Downgrade Janney Buy → Neutral
May-21-18Resumed Leerink Partners Mkt Perform
Mar-14-18Reiterated B. Riley FBR, Inc. Neutral $16 → $23
Feb-15-18Upgrade Janney Neutral → Buy
Dec-07-17Initiated B. Riley FBR, Inc. Neutral $16
Oct-23-17Initiated Piper Jaffray Neutral $18
Sep-08-17Initiated Morgan Stanley Overweight $26
Jan-11-17Downgrade Needham Buy → Hold
Jan-10-17Downgrade Leerink Partners Outperform → Mkt Perform
Jan-09-17Downgrade Raymond James Mkt Perform → Underperform
Oct-27-16Initiated Needham Buy $40
May-09-16Reiterated Deutsche Bank Hold $42 → $35
May-04-16Downgrade Raymond James Outperform → Mkt Perform
Jan-21-16Initiated Barclays Equal Weight $32
Jul-06-20 10:00AM  
Jun-11-20 01:55PM  
Jun-10-20 11:30AM  
May-27-20 08:00AM  
May-21-20 05:00PM  
May-12-20 12:26PM  
May-11-20 12:00PM  
May-06-20 06:51AM  
May-05-20 06:13AM  
Apr-28-20 12:33PM  
Apr-27-20 04:30PM  
Apr-16-20 08:00AM  
Apr-03-20 11:30AM  
Apr-02-20 01:23PM  
Mar-25-20 12:00PM  
Mar-13-20 03:59AM  
Mar-09-20 09:49AM  
Mar-05-20 08:21AM  
Mar-04-20 08:35AM  
Mar-01-20 08:31AM  
Feb-28-20 08:00AM  
Feb-26-20 08:46AM  
Feb-19-20 08:53AM  
Feb-14-20 04:34PM  
Feb-10-20 05:40PM  
Feb-03-20 03:05PM  
Jan-30-20 12:31PM  
Jan-27-20 02:45PM  
Jan-24-20 06:12PM  
Jan-21-20 06:15PM  
Jan-14-20 11:05PM  
Jan-10-20 06:08PM  
Jan-09-20 05:43PM  
Jan-03-20 08:00AM  
Dec-18-19 08:00AM  
Dec-13-19 11:12AM  
Dec-06-19 08:00AM  
Dec-02-19 08:20AM  
Dec-01-19 09:30AM  
Nov-26-19 09:19AM  
Nov-19-19 04:54PM  
Nov-16-19 08:18AM  
Nov-13-19 02:14PM  
Nov-07-19 05:44PM  
Nov-06-19 06:18AM  
Nov-05-19 03:35AM  
Nov-04-19 11:18AM  
Nov-01-19 12:25PM  
Oct-31-19 11:36AM  
Oct-30-19 04:23PM  
Oct-29-19 09:40PM  
Oct-28-19 04:21PM  
Oct-27-19 12:56PM  
Oct-25-19 10:30AM  
Oct-24-19 08:00AM  
Oct-11-19 08:00AM  
Oct-08-19 08:45AM  
Sep-28-19 09:05AM  
Sep-26-19 08:00AM  
Sep-25-19 08:00AM  
Sep-23-19 08:00AM  
Sep-20-19 08:44AM  
Sep-16-19 08:00AM  
Sep-12-19 08:00AM  
Sep-06-19 09:31AM  
Sep-05-19 06:24AM  
Sep-04-19 05:56PM  
Aug-30-19 09:29PM  
AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ARMISTICE CAPITAL, LLC10% OwnerMar 16Buy4.8724,000116,880348,000Mar 18 04:52 PM
ARMISTICE CAPITAL, LLC10% OwnerFeb 25Buy8.2936,000298,440324,000Feb 27 05:27 PM
ARMISTICE CAPITAL, LLC10% OwnerJan 27Buy9.418,00075,280288,000Jan 28 04:48 PM
ARMISTICE CAPITAL, LLC10% OwnerJan 27Buy9.438,00075,4404,120,000Jan 28 04:48 PM
ARMISTICE CAPITAL, LLC10% OwnerJan 24Buy9.7240,000388,800280,000Jan 28 04:48 PM
ARMISTICE CAPITAL, LLC10% OwnerJan 24Buy9.5834,000325,7204,112,000Jan 28 04:48 PM
ARMISTICE CAPITAL, LLC10% OwnerJan 10Buy11.6418,000209,5204,078,000Jan 13 05:47 PM
ARMISTICE CAPITAL, LLC10% OwnerJan 09Buy12.3312,466153,7064,060,000Jan 13 05:47 PM
ARMISTICE CAPITAL, LLC10% OwnerJan 09Sale12.4312,466154,9524,047,534Jan 13 05:47 PM
Camber Capital Management LP10% OwnerAug 09Buy8.9730,000268,9964,390,000Aug 09 03:41 PM
ARMISTICE CAPITAL, LLC10% OwnerAug 07Buy7.4340,000297,200240,000Aug 09 05:05 PM
ARMISTICE CAPITAL, LLC10% OwnerAug 07Buy7.32260,0001,903,2004,060,000Aug 09 05:05 PM
Camber Capital Management LP10% OwnerAug 07Buy7.78355,0002,760,7964,360,000Aug 09 03:41 PM